Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 4/2014

01-04-2014 | Original Article

In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor

Authors: Ling Gao, Michael M. Yue, Jennifer Davis, Elisabeth Hyjek, Lucia Schuger

Published in: Virchows Archiv | Issue 4/2014

Login to get access

Abstract

Lymphangioleiomyomatosis (LAM) of the lung is a rare low-grade malignancy affecting primarily women of childbearing age. LAM is characterized by the proliferation of SMA and HMB-45 positive spindle-shaped and epithelioid cells throughout the lung in the form of discrete lesions causing cystic destruction and ultimately respiratory insufficiency. LAM occurs sporadically or in patients with tuberous sclerosis complex (TSC) and is etiologically linked to mutations in the TSC1 and TSC2 genes. Although LAM cells are known to express estrogen and progesterone receptors (ER and PR, respectively), their respective expression level was never determined. Therefore, here we measured the immunohistochemical expression of ERs and PRs in a large series of pulmonary LAM cases using the Aperio Spectrum Analysis Platform. Our case series comprised open lung biopsy specimens from 20 LAM patients and lungs explanted during the course of lung transplant from 24 patients. All cases were positive for ER and PR. PR expression was statistically significantly higher than ER in 80 % of the biopsies while ER predominated only in one case. Specimens from explanted cases of LAM had relatively fewer PR-positive nuclei. As a result, PR expression was significantly higher than ER in 38 % of the cases, whereas ER predominated in 33 %. Overall, PR expression predominated in 57 % of cases and ER in 21 %. These data indicate that PR frequently prevails over ER in pulmonary LAM. LAM is unusual in its high PR/ER ratio; other female neoplasms show a definite prevalence of ER. Our findings therefore warrant further study of PR function in LAM.
Appendix
Available only for authorised users
Literature
1.
McCormack FX, Travis WD, Colby TV, Henske EP, Moss J (2012) Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 186:1210–1212PubMedCentralPubMedCrossRef
2.
3.
Cottin V, Archer F, Leroux C, Mornex JF, Cordier JF (2011) Milestones in lymphangioleiomyomatosis research. Eur Respir Rev 20:3–6PubMedCrossRef
4.
5.
Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O (2002) Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 47:20–28PubMedCrossRef
6.
Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP (2003) Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167:976–982PubMedCrossRef
7.
Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J (2004) Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 101:17462–17467PubMedCentralPubMedCrossRef
8.
Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA, Riemenschn W, Matsui K, Travis WD, Moss J (2000) Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch 67:311–329PubMedCrossRef
9.
Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J (1999) Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 21:327–336PubMedCrossRef
10.
Bonetti F, Chiodera P, Pea M, Martignoni G, Bosi F, Zamboni G, Mariuzzi GM (1993) Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB-45 for diagnosis. Am J Surg Pathol 17:1092–1102PubMedCrossRef
11.
Hoon V, Thung SN, Kaneko N, Unger PD (1994) HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. Arch Pathol Lab Med 118:732–734PubMed
12.
Zhe X, Schuger L (2004) Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 52:1537–1542PubMedCrossRef
13.
Astrinidis A, Henske EP (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24:7475–7481PubMedCrossRef
14.
Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2:R251–R258CrossRef
15.
Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345–1356PubMedCrossRef
16.
Hohman DW, Noghrehkar D, Ratnayake S (2008) Lymphangioleiomyomatosis: A review. Eur J Intern Med 19:319–324PubMedCrossRef
17.
Chorianopoulos D, Stratakos G (2008) Lymphangioleiomyomatosis and tuberous sclerosis complex. Lung 186:197–207PubMedCrossRef
18.
Bittman I, Rolf B, Amann G, Lohrs U (2003) Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol 34:95–98CrossRef
19.
Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP (2001) The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med 163:253–258PubMedCrossRef
20.
Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97:6085–6090PubMedCentralPubMedCrossRef
21.
van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S et al (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805–808PubMedCrossRef
22.
European chromosome 16 tuberous sclerosis consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305–1315CrossRef
23.
Castro AF, Rebhun JF, Clark GG, Quilliam LA (2003) Rheb binds TSC2 and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 278:32493–32496PubMedCrossRef
24.
Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457–1466PubMedCrossRef
25.
26.
Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D et al (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578–581PubMedCrossRef
27.
Tomasoni R, Mondino A (2011) The tuberous sclerosis complex: balancing proliferation and survival. Biochem Soc Trans 39:466–471PubMedCrossRef
28.
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140–151PubMedCentralPubMedCrossRef
29.
McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:1595–1606PubMedCentralPubMedCrossRef
30.
Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J (2011) Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 154:797–805PubMedCentralPubMedCrossRef
31.
Cohen MM, Freyer AM, Johnson SR (2009) Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med 103:766–772PubMedCrossRef
32.
Saleh Gargari S, Hantoushzadae S, Mohamadi F, Jafar-Abadi M (2009) Pregnancy complicated by lymphangioleiomyomatosis. Arch Iran Med 12:182–185PubMed
33.
34.
Matsui K, Takeda K, Yu ZX, Valencia J, Travis WD, Moss J, Ferrans VJ (2000) Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med 161:1002–1009PubMedCrossRef
35.
Matsui K, Tatsuguchi A, Valencia J, Zx Y, Bechtle J, Beasley MB, Avila N, Travis WD, Moss J, Ferrans VJ (2000) Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 31:1242–1248PubMedCrossRef
36.
Flavin RJ, Cook J, Fiorentino M, Bailey D, Brown M, Loda MF (2011) β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. Am J Clin Pathol 135:776–782PubMedCrossRef
37.
Wakamiya T, Sugita Y, Hashiguchi M, Iwasaka T, Tokunaga O (2011) Tuberous sclerosis complex associated with papillary serous carcinoma of the peritoneum, lymphangioleiomyomatosis, and angiomyolipoma. Case Report Pathol 2011:564260
38.
Mitani K, Kumasaka T, Takemura H, Hayashi T, Gunji Y, Kunogi M, Akiyoshi T, Takahashi K, Suda K, Seyama K (2009) Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis. Acta Cytol 53:402–409PubMedCrossRef
39.
Pan LH, Ito H, Kurose A, Yamauchi K, Inoue H, Sawai T (2003) Pulmonary lymphangioleiomyomatosis: a case report with immunohistochemical details and DNA analysis. Tohoku J Exp Med 199:119–126PubMedCrossRef
40.
Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP (2009) Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A 106:2635–2640PubMedCentralPubMedCrossRef
41.
Denoo X, Hermans G, Degives R, Foidart JM (1999) Successful treatment of pulmonary lymphangioleiomyomatosis with progestins: a case report. Chest 115:276–279PubMedCrossRef
42.
Baldi BG, Medeiros Junior P, Pimenta SP, Lopes RI, Kairalla RA, Carvalho CR (2011) Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis. J Bras Pneumol 37:375–379PubMedCrossRef
43.
Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J (2008) Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest 133:448–454PubMedCentralPubMedCrossRef
44.
Schiavina M, Contini P, Fabiani A, Cinelli F, Di Scioscio V, Zompatori M, Campidelli C, Pileri SA (2007) Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients. Sarcoidosis Vasc Diffuse Lung Dis 24:39–50PubMed
45.
Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J (2004) Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126:1867–1874PubMedCrossRef
46.
Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, Cordier JF (1999) Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 78:321–337CrossRef
47.
Liang YJ, Hao Q, Zhang HM, Wu YZ, Wang JD (2012) Insulin-like growth factors in endometrioid adenocarcinoma: correlation with clinico-pathological features and estrogen receptor expression. BMC Cancer 12:262PubMedCentralPubMedCrossRef
48.
49.
Badri KR, Gao L, Hyjek E, Schuger N, Schuger L, Qin W, Chekaluk Y, Kwiatkowski DJ, Zhe X (2013) Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis (LAM). Am J Respir Crit Care Med 187:663–665PubMedCentralPubMedCrossRef
50.
Yu J, Astrinidis A, Howard S, Henske EP (2004) Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 286:L694–L700PubMedCrossRef
51.
Ueng SH, Liu HP, Wu YC, Tsai YH, Lin HC, Lin MC, Lim KE, Huang SF (2004) Pulmonary lymphangioleiomyomatosis: a clinicopathological analysis of ten cases. Chang Gung Med J 27:201–209PubMed
52.
Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J (2012) Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol 7:27PubMedCentralPubMedCrossRef
53.
van der Horst PH, Wang Y, Vandenput I, Kühne LC, Ewing PC, van Ijcken WF, van der Zee M, Amant F, Burger CW, Blok LJ (2012) Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One 7:e30840PubMedCentralPubMedCrossRef
54.
Wang Y, van der Zee M, Fodde R, Blok LJ (2010) Wnt/Β-Catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget 1:674–684PubMedCentralPubMed
55.
Wang Y, Hanifi-Moghaddam P, Hanekamp EE, Kloosterboer HJ, Franken P, Veldscholte J, van Doorn HC, Ewing PC, Kim JJ, Grootegoed JA, Burger CW, Fodde R, Blok LJ (2009) Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 15:5784–5793PubMedCrossRef
56.
Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC, Giulianelli S, Cerliani JP, Wargon V, Molinolo A (2009) The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 16:333–350PubMedCrossRef
57.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef
58.
Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427PubMedCrossRef
59.
60.
61.
Riggio M, Polo ML, Blaustein M, Colman-Lerner A, Lüthy I, Lanari C, Novaro V (2012) PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer. Carcinogenesis 33:509–518PubMedCrossRef
62.
Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV (2003) Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575–588PubMedCrossRef
63.
Grunt TW, Mariani GL (2012) Targeting the PI3K/AKT/mTOR pathway in breast cancer. Curr Cancer Drug Targets 21:177–184
64.
Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP (2011) Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126:113–120PubMedCrossRef
Metadata
Title
In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor
Authors
Ling Gao
Michael M. Yue
Jennifer Davis
Elisabeth Hyjek
Lucia Schuger
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 4/2014
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-014-1559-9

Other articles of this Issue 4/2014

Virchows Archiv 4/2014 Go to the issue

Original Article

microRNA expression might predict prognosis of epithelial hepatoblastoma

Case Report

Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation

Original Article

Morphology predicts BRAF V600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study

Original Article

Reproducibility of histopathologic tumor grading in penile cancer—results of a European project

Original Article

Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems

Original Article

Stem cell marker-positive stellate cells and mast cells are reduced in benign-appearing bladder tissue in patients with urothelial carcinoma